<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00678145</url>
  </required_header>
  <id_info>
    <org_study_id>2012-665</org_study_id>
    <secondary_id>R01DK079974</secondary_id>
    <nct_id>NCT00678145</nct_id>
  </id_info>
  <brief_title>Mechanisms of Hypoglycemia Associated Autonomic Failure</brief_title>
  <official_title>Mechanisms of Hypoglycemia Associated Autonomic Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intensive glucose control in type 1 diabetes mellitus (T1DM) is associated with clear health&#xD;
      benefits (1). However, despite development of insulin analogs, pump/multi-dose treatment and&#xD;
      continuous glucose monitoring, maintaining near-normal glycemia remains an elusive goal for&#xD;
      most patients, in large part owing to the risk of hypoglycemia. T1DM patients are susceptible&#xD;
      to hypoglycemia due to defective counterregulatory responses (CR) characterized by: 1)&#xD;
      deficient glucagon release during impending/early hypoglycemia; 2) additional&#xD;
      hypoglycemia-associated autonomic failure (HAAF) and exercise-associated autonomic failure&#xD;
      (EAAF) that blunt the sympathoadrenal responses to hypoglycemia following repeated episodes&#xD;
      of hypoglycemia or exercise as well as degrading other CR; and 3) hypoglycemia unawareness&#xD;
      (HU), lowering the threshold for symptoms that trigger behavioral responses (e.g. eating).&#xD;
      Thus, the risk of hypoglycemia in T1DM impedes ideal insulin treatment and leads to&#xD;
      defaulting to suboptimal glycemic control (2). There are two approaches that could resolve&#xD;
      this important clinical problem: 1) perfection of glucose sensing and insulin and glucagon&#xD;
      delivery approaches (bioengineered or cell-based) that mimic normal islet function and&#xD;
      precisely regulate glucose continuously, or 2) a drug to enhance or normalize the pattern of&#xD;
      CR to hypoglycemia. Despite much research and important advances in the field, neither islet&#xD;
      transplantation nor biosensor devices have emerged as viable long-term solutions for the&#xD;
      majority of patients (3, 4). Over the past several years, our lab has explored the approach&#xD;
      of enhancing CR by examining mechanisms responsible for HAAF/EAAF and searching for potential&#xD;
      pharmacological methods to modulate the CR to hypoglycemia (5-11). Our work has led to a&#xD;
      paradigm shift in the field of hypoglycemia, exemplified by the novel hypothesis and&#xD;
      published experimental data supporting a role for opioid signaling that resulted in the&#xD;
      initiation of exploratory clinical trials by other research groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the prior project period of R01 DK079974, we elucidated the central role played by the&#xD;
      opioid signaling system as a mechanism for the development of HAAF/EAAF. We have demonstrated&#xD;
      previously that opioid receptor blockade by acute infusion of naloxone during antecedent&#xD;
      hypoglycemia can prevent experimentally induced HAAF in nondiabetic and T1DM subjects (JCEM&#xD;
      94:3372-80, 2009; JCEM 96:3424-31, 2011). We have also shown that opioid receptor blockade&#xD;
      also abolishes EAAF, and that both effects are regulated by the stress response (hypoglycemia&#xD;
      and exercise, respectively). Furthermore, recently we have shown that activation of Î¼-opioid&#xD;
      receptors with IV infusion of morphine reproduces some of the key biochemical and clinical&#xD;
      features of HAAF in nondiabetic humans.Taken together, these studies demonstrate that the&#xD;
      opioid system plays a central role in hypoglycemia counterregulation and in HAAF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2008</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the counterregulatory responses to hypoglycemia compared to controls</measure>
    <time_frame>Measured every 15 minutes at timepoints 0, 15, 30, 45...120 through study completion</time_frame>
    <description>Measurements of counterregulatory hormones will be measured throughout the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom scores</measure>
    <time_frame>Measured every 15 minutes at timepoints 0, 15, 30, 45...120 through study completion</time_frame>
    <description>Symptoms of hypoglycemia will be taken during the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Hypoglycemia</condition>
  <condition>Autonomic Failure</condition>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy individuals will receive drug (naloxone, morphine sulfate, epinephrine) and placebo comparator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 1 Diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T1D individuals will receive drug (naloxone, morphine sulfate, epinephrine) and placebo comparator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naloxone</intervention_name>
    <description>Administering naloxone on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.</description>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Type 1 Diabetes</arm_group_label>
    <other_name>Narcan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>fructose</intervention_name>
    <description>Administering fructose on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.</description>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Type 1 Diabetes</arm_group_label>
    <other_name>Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>exercise</intervention_name>
    <description>Administering exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.</description>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Type 1 Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine sulfate</intervention_name>
    <description>Administering morphine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.</description>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Type 1 Diabetes</arm_group_label>
    <other_name>Morphine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>Administering epinephrine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.</description>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Type 1 Diabetes</arm_group_label>
    <other_name>Adrenalin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-diabetic individuals&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Hyperlipidemia&#xD;
&#xD;
          -  Heart disease&#xD;
&#xD;
          -  Cerebrovascular disease&#xD;
&#xD;
          -  Seizures&#xD;
&#xD;
          -  Bleeding disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meredith Hawkins, M.D., M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine / General Clinical Research Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 14, 2008</study_first_submitted>
  <study_first_submitted_qc>May 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2008</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Meredith Hawkins</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>HAAF</keyword>
  <keyword>Counterregulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pure Autonomic Failure</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

